Bora CDMO Bora CDMO

X

Find the latest Drugs in Development and Pipeline Prospector News of Healios K.K.

  • Webinars & Exhibitions

PharmaCompass
Send me more info on How To Grow My Bussiness Digitally?
Healios K.K
japan Flag
Country
Country
Japan
Address
Address
World Trade Center Bldg. 15F 2-4-1 Hamamatsucho Minato-ku, Tokyo 105-6115
Telephone
Telephone
Linkedin
Linkedin
Twitter
Twitter

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Details:

Healios reported that last patient in its Phase 2/3 TREASURE study, evaluating MultiStem, a patented regenerative medicine product for the treatment of ischemic stroke, completed the 365-day follow-up visit.


Lead Product(s): Invimestrocel

Therapeutic Area: Cardiology/Vascular Diseases Product Name: MultiStem

Highest Development Status: Phase IIIProduct Type: Cell and Gene therapy

Partner/Sponsor/Collaborator: Athersys

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable April 04, 2022

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

This agreement will enable both Athersys and Healios to focus on advancing their late-stage programs for MultiStem, including preparing for top line results from Healios’ TREASURE trial for stroke and ONE-BRIDGE trial for ARDS, which is expected this year.


Lead Product(s): MultiStem

Therapeutic Area: Neurology Product Name: HLCM051

Highest Development Status: Phase IIIProduct Type: Cell and Gene therapy

Recipient: Athersys

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Agreement February 16, 2021

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

HEALIOS K.K continues to make enrolment progress in its ONE-BRIDGE study, a phase II clinical trial in Japan evaluating the safety and efficacy of HLCM051.


Lead Product(s): HLCM051

Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

Highest Development Status: Phase IIProduct Type: Cell and Gene therapy

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable April 14, 2020

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

The SSC candidate of Healios (HLCM051) is in an ischemic stroke pivotal phase 2/3 trial in Japan in which it offers the potential to provide effective treatment over a much longer treatment window.


Lead Product(s): HLCM051

Therapeutic Area: Cardiology/Vascular Diseases Product Name: Undisclosed

Highest Development Status: Phase II/ Phase IIIProduct Type: Cell and Gene therapy

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable January 09, 2020

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty
Post Enquiry
POST ENQUIRY